Artiva Biotherapeutics
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren disease. Artiva was founded in 2019 as a spin out of GC Cell in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding APAC) to GC Cell’s NK cell manufacturing technology and programs. Artiva is headquartered in San Diego, California.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
AlloNK® (also known as AB-101), an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion.
CEO
Fred Aslan
Development Phase of Lead Product
Phase II
Exchange
Nasdaq
Ticker
ARTV
When you expect your next catalyst update?
June 2026 (updated data will be presented at BIO)
What is your next catalyst (value inflection) update?
Initial clinical efficacy data in 1H 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}